Increased concentration of clusterin/apolipoprotein J (apoJ) in hyperlipemic serum is paradoxically associated with decreased apoJ content in lipoproteins

Atherosclerosis

Volumn 241, Issue 2, 2015, Pages 463-470

  Rull, Anna ^a   Martínez Bujidos, Maria ^a,b   Pérez Cuellar, Montserrat ^a   Pérez, Antonio ^a   Ordóñez Llanos, Jordi ^a,b   Sánchez Quesada, José Luis ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Apolipoprotein J; Atherosclerosis; Cardiovascular risk factors; Hyperlipidemia; Lipoproteins

Indexed keywords

CHOLESTEROL; CLUSTERIN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; APOLIPOPROTEIN C3; CLU PROTEIN, HUMAN; LIPID;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN LOCALIZATION; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION; AGED; BLOOD; METABOLISM; RISK FACTOR;

ADULT; AGED; APOLIPOPROTEIN C-III; CHOLESTEROL; CLUSTERIN; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; RISK FACTORS; TRIGLYCERIDES;

EID: 84931282064     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.06.003     Document Type: Article

References (40)

1. Trougakos I.P. The molecular chaperone apolipoprotein J/clusterin as a sensor of oxidative stress: implications in therapeutic approaches - a mini-review. Gerontology 2013, 59:514-523.
2. Yerbury J.J., Poon S., Meehan S., et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 2007, 21:2312-2322.
3. de Silva H.V., Stuart W.D., Duvic C.R., et al. A70-kDa apolipoprotein designated apoJ is a marker for subclasses of human plasma high density lipoproteins. J.Biol. Chem. 1990, 265:13240-13247.
4. de Silva H.V., Stuart W.D., Park Y.B., et al. Purification and characterization of apolipoprotein J. J.Biol. Chem. 1990, 265:14292-14297.
5. Aronow B.J., Lund S.D., Brown T.L., et al. Apolipoprotein J expression at fluid-tissue interfaces: potential role in barrier cytoprotection. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:725-729.
6. de Silva H.V., Harmony J.A., Stuart W.D., et al. Apolipoprotein J: structure and tissue distribution. Biochemistry 1990, 29:5380-5389.
7. Ishikawa Y., Ishii T., Akasaka Y., et al. Immunolocalization of apolipoproteins in aortic atherosclerosis in American youths and young adults: findings from the PDAY study. Atherosclerosis 2001, 158:215-225.
8. Ishikawa Y., Akasaka Y., Ishii T., et al. Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta. Arterioscler. Thromb. Vasc. Biol. 1998, 18:665-672.
9. Mackness B., Hunt R., Durrington P.N., et al. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 1997, 17:1233-1238.
10. Miyata M., Biro S., Kaieda H., et al. Apolipoprotein J/clusterin is induced in vascular smooth muscle cells after vascular injury. Circulation 2001, 104:1407-1412.
11. Cubedo J., Padro T., Garcia-Moll X., et al. Proteomic signature of apolipoprotein J in the early phase of new-onset myocardial infarction. J.Proteome Res. 2011, 10:211-220.
12. Won J.C., Park C.Y., Oh S.W., et al. Plasma clusterin (ApoJ) levels are associated with adiposity and systemic inflammation. PLoS One 2014, 9:e103351.
13. Riwanto M., Rohrer L., Roschitzki B., et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 2013, 127:891-904.
14. Hoofnagle A.N., Wu M., Gosmanova A.K., et al. Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia. Arterioscler. Thromb. Vasc. Biol. 2010, 30:2528-2534.
15. Poulakou M.V., Paraskevas K.I., Vlachos I.S., et al. Effect of statins on serum apolipoprotein j and paraoxonase-1 levels in patients with ischemic heart disease undergoing coronary angiography. Angiology 2008, 59:137-144.
16. Poulakou M.V., Paraskevas K.I., Wilson M.R., et al. Apolipoprotein J and leptin levels in patients with coronary heart disease. InVivo 2008, 22:537-542.
17. Kujiraoka T., Hattori H., Miwa Y., et al. Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. J.Atheroscler. Thromb. 2006, 13:314-322.
18. Morrissey C., Lakins J., Moquin A., et al. An antigen capture assay for the measurement of serum clusterin concentrations. J.Biochem. Biophys. Methods 2001, 48:13-21.
19. Navab M., Hama-Levy S., Van Lenten B.J., et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J.Clin. Invest. 1997, 99:2005-2019.
20. Navab M., Anantharamaiah G.M., Reddy S.T., et al. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1932-1937.
21. Kelso G.J., Stuart W.D., Richter R.J., et al. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 1994, 33:832-839.
22. Sun H.Y., Chen S.F., Lai M.D., et al. Comparative proteomic profiling of plasma very-low-density and low-density lipoproteins. Clin. Chim. Acta 2009, 411:336-344.
23. Karlsson H., Leanderson P., Tagesson C., et al. Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5:551-565.
24. Bancells C., Canals F., Benitez S., et al. Proteomic analysis of electronegative low-density lipoprotein. J.Lipid Res. 2010, 51:3508-3515.
25. Schwarz M., Spath L., Lux C.A., et al. Potential protective role of apoprotein J (clusterin) in atherogenesis: binding to enzymatically modified low-density lipoprotein reduces fatty acid-mediated cytotoxicity. Thromb. Haemost. 2008, 100:110-118.
26. Martinez-Bujidos M., Rull A., Gonzalez-Cura B., et al. Clusterin/apolipoprotein J binds to aggregated LDL in human plasma and plays a protective role against LDL aggregation. FASEB J. 2015, 29:1688-1700.
27. Trougakos I.P., Poulakou M., Stathatos M., et al. Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp. Gerontol. 2002, 37:1175-1187.
28. Trougakos I.P., Gonos E.S. Clusterin/apolipoprotein J in human aging and cancer. Int. J. Biochem. Cell Biol. 2002, 34:1430-1448.
29. Pettersson C., Karlsson H., Stahlman M., et al. LDL-associated apolipoprotein J and lysozyme are associated with atherogenic properties of LDL found in type 2 diabetes and the metabolic syndrome. J.Intern Med. 2011, 269:306-321.
30. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J.Clin. Invest. 1955, 34:1345-1353.
31. Stahlman M., Davidsson P., Kanmert I., et al. Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J.Lipid Res. 2008, 49:481-490.
32. Park S., Mathis K.W., Lee I.K. The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases. Rev. Endocr. Metab. Disord. 2014, 15:45-53.
33. Vaisar T., Pennathur S., Green P.S., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J.Clin. Invest. 2007, 117:746-756.
34. Burillo E., Mateo-Gallego R., Cenarro A., et al. Beneficial effects of omega-3 fatty acids in the proteome of high-density lipoprotein proteome. Lipids Health Dis. 2012, 11:116.
35. Arnold T., Brandlhofer S., Vrtikapa K., et al. Effect of obesity on plasma clusterin, [corrected] a proposed modulator of leptin action. Pediatr. Res. 2011, 69:237-242.
36. Allayee H., Castellani L.W., Cantor R.M., et al. Biochemical and genetic association of plasma apolipoprotein A-II levels with familial combined hyperlipidemia. Circ. Res. 2003, 92:1262-1267.
37. Chan D.C., Ng T.W., Watts G.F. Apolipoprotein A-II: evaluating its significance in dyslipidaemia, insulin resistance, and atherosclerosis. Ann. Med. 2012, 44:313-324.
38. White C.R., Garber D.W., Anantharamaiah G.M. Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review. J.Lipid Res. 2014, 55:2007-2021.
39. Huang Y.C., Chang P.Y., Hwang J.S., et al. Association of small dense low-density lipoprotein cholesterol in type 2 diabetics with coronary artery disease. Biomed. J. 2014, 37:375-379.
40. Sharma S.B., Garg S. Small dense LDL: risk factor for coronary artery disease (CAD) and its therapeutic modulation. Indian J. Biochem. Biophys. 2012, 49:77-85.